FHA
GRCE

Flagship Harbor Advisors’s Grace Therapeutics GRCE Stock Holding History

Flagship Harbor Advisors’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2
Closed -$7 – 2286
2025
Q4 		$7 Buy
+2
New +$6 ﹤0.01% 2266

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Flagship Harbor Advisors's GRCE Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of Grace Therapeutics (GRCE) in Q1 2026, closing a stake of 2 shares — an estimated $7 sold.

Flagship Harbor Advisors first reported a position in GRCE in Q4 2025 and held it in 1 quarter. The position peaked at $7 in Q4 2025. 34 funds tracked by Wall St. Rank hold GRCE as of Q1 2026.

  • Flagship Harbor Advisors reported no remaining Grace Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Flagship Harbor Advisors sold 2 Grace Therapeutics shares in Q1 2026, an estimated $7.
  • Flagship Harbor Advisors first reported a position in Grace Therapeutics in Q4 2025 and held it in 1 quarter.
  • Flagship Harbor Advisors's Grace Therapeutics position peaked at $7 in Q4 2025.
  • 34 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.